Ceribell, Inc. · NASDAQ:CBLL
Ceribell — J.P. Morgan Healthcare Conference 2026
32 slides from Ceribell's conference presentation, January 2026
Slide 1: Corporate Presentation
Corporate Presentation January 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about the Company and its industry. These statements and the outcomes of the events they describe involve substantial risks, uncertainties and
Slide 3: AI-Powered Point-of-Care EEG Platform Targeting Serious Neurological Conditions in the Acute Care Setting
AI-Powered Point-of-Care EEG Platform Targeting Serious Neurological Conditions in the Acute Care Setting 3
Slide 4: Large & Expanding Market Opportunity; Financial Highlights
Large & Expanding Market Opportunity Financial Highlights U.S. only >$3.5B $87M - $89M FY 2025 Revenue 1 Delirium >$2B Pediatric & Neonate Seizure Acute Care 34% YoY Revenue Growth 2 Adult Seizure Adult Seizure Acute Care Market Acute Care Market 2025 TAM With Recently 88% Expanded Indications Gross
Slide 5: Seizures Are Highly Prevalent in Critically-Ill Patients and Often Go Undiagnosed
Seizures Are Highly Prevalent in Critically-Ill Patients and Often Go Undiagnosed Patient Population Estimated Prevalence of Seizures1 Following Convulsive Status Epilepticus (SE) 48% Hypoxic-Ischemic Encephalopathy Post Cardiac Arrest 10-59% Sepsis-Associated Encephalopathy 32% 92% Brain Tumors 23-
Slide 6: "Time is Brain"
"Time is Brain" STATUS EPILEPTICUS PATIENT RESPONSE RATE TO ALL-CAUSE MORBIDITY & MORTALITY RATE 1 FIRST-LINE TREATMENT2 80% 75% 15% 61% Morbidity 50% Mortality 50% 40% 85% 30% 33% 10% <10 hr 10-20 hr >20 hr <0.5 <1.0 <1.5 <2.0 ≥2.0 >2.0 DURATION OF SEIZURE (Hrs) TREATMENT DELAY (Hrs) 1. Young, G.B.
Slide 7: Guidelines and Recommendations Include Timely EEG to Detect and Manage Seizures
Guidelines and Recommendations Include Timely EEG to Detect and Manage Seizures Across Different Disease States EEG should be initiated within 15-60 minutes to “evaluate for NCSE if [patient is] not 2012 waking up after clinically obvious seizures cease.” 1 “Recommend promptly performing and interpr
Slide 8: Conventional EEG Has Significant Limitations in the Acute Care Setting
Conventional EEG Has Significant Limitations in the Acute Care Setting Overview of EEG Conventional EEG systems were not designed for the acute care setting Hardware & Access Challenges An EEG is a non-invasive tool used to measure and display electrical activity in the brain Requires EEG Technician
Slide 9: Clinical Reality: Conventional EEG is Not Suited for the Acute Care Setting and Leads to Long Delays
Clinical Reality: Conventional EEG is Not Suited for the Acute Care Setting and Leads to Long Delays 2 1 3 EEG Arrival & Set-Up Seizure Suspicion / EEG Order EEG Interpretation Continuous Review of EEG Hours or Days1,2,3 Records is Rare4 1.Gururangan, K., et al. (2016) Clinical Neurophysiology. 127(
Slide 10: Ceribell EEG System: Suspicion to Diagnosis in Minutes
Ceribell EEG System: Suspicion to Diagnosis in Minutes, Enabling Earlier & More Accurate Treatment The System Seizure Suspicion / EEG Arrival & 1 2 3 EEG Interpretation EEG Order Set-Up ~5 Minutes to Set Up1 Early detection Continuous monitoring By any trained, non-specialized healthcare professiona
Slide 11: The Ceribell System: Portable Hardware with AI-Powered Algorithms
The Combining highly portable, simple-to-use and System rapidly deployable hardware with AI-powered algorithms Ceribell EEG Portal Ceribell EEG Headband AI-powered Seizure Detection Ceribell EEG Recorder Algorithm 11
Slide 12: Clarity: Our Proprietary AI-Powered Seizure Detection Algorithm
Clarity: Our Proprietary AI-Powered Seizure Detection Algorithm ✓Bed-side Alert ✓Real-time feedback on response to medication ✓Provides seizure burden to facilitate EEG reading for neurologists 12 CAUTION: Device does not substitute for EEG review by a qualified clinician. Before use, review the man
Slide 13: Ceribell Supports Precise Patient Care for SE: Expediting Diagnosis and Continuously Monitoring
Ceribell Supports Precise Patient Care for SE: Expediting Diagnosis and Continuously Monitoring Seizure Burden 13 CAUTION: Device does not substitute for EEG review by a qualified clinician. Before use, review the manual for indications, contraindications, warnings, precautions, potential adverse ev
Slide 14: Evidence-Based Clinical & Economic Benefits
Evidence-Based Clinical & Economic Benefits 47 Peer-Reviewed Publications & 97 Abstracts Study Findings SAFER Study Overview The Seizure Assessment and convEEG Ceribell Forecasting with Efficient Rapid- Outcome ∆ Delta P- Value (N = 62) (N = 62)2 EEG (SAFER-EEG) study is a multisite retrospective st
Slide 15: Business Model: Two Sources of Recurring Revenue
Business Model: Two Sources of Recurring Revenue ~75% Product Recurring (single-patient disposable) ~25% Subscription Revenue (SaaS + loaned capital) Single-Use Headband + + Disposable AI Algorithm Recorder Portal SaaS Capital SaaS 15 CAUTION: Device does not substitute for EEG review by a qualified
Slide 16: Rapid Commercial Expansion & Projectable Business Model
Rapid Commercial Expansion & Projectable Business Model Quarterly Revenue ($ in million) $22.6 $21.2 $20.5 $18.5 $17.0 $15.3 $14.4 $13.1 $11.6 $10.9 $9.5 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 16
Slide 17: Significant Opportunity For Continued Growth Within Core Seizure Market
Significant Opportunity For Continued Growth Within Core Seizure Market 3% of addressable Market* 10% hospital penetration* x 30% within existing accounts* Ceribell is currently active in only Ceribell’s top customers use 615 out of roughly 6,000 hospitals approximately 3x the number of providing ac
Slide 18: 2026 Strategic Objectives of Core Seizure Market
2026 Strategic Objectives of Core Seizure Market Account Acquisition Drive Utilization in Existing Accounts • Execute on proven account acquisition strategy • Expand to new departments, ER, ICUs • Drive productivity of recently expanded commercial • Train more providers in all shifts infrastructure
Slide 19: Neonate & Pediatric Indication Expansion
2025 Milestones - Seizure Market Expansion Neonate & Pediatric Indication Expansion • Received FDA clearances for Clarity algorithms for age 1+ and neonate, including pre-term • Unlocked incremental $400M market opportunity, including ~280 children's hospitals targets • Initiated successful pilots i
Slide 20: Approved November 2025: Ceribell Neonate EEG system
Approved November 2025: Ceribell Neonate EEG system 20 CAUTION: Device does not substitute for EEG review by a qualified clinician. Before use, review the manual for indications, contraindications, warnings, precautions, potential adverse events and Instructions for Use. Sale requires the order of a
Slide 21: Seizures in Critically Ill Neonates are Common, Requiring EEG for Accurate Diagnosis
Seizures in Critically Ill Neonates are Common, Requiring EEG for Accurate Diagnosis Diagnostic challenges can lead to Seizures are the most common under- and over-treatment neurological emergency in newborns up to Patient Population Prevalence of Seizures3,4 90% of neonatal seizures are non-convuls
Slide 22: Neonatal Seizures Require Urgent Diagnosis and Management
Neonatal Seizures Require Urgent Diagnosis and Management 1 hour in seizure is associated with Just 1 hour delay to treat seizure may lead to worse language and neurocognitive impairment1 higher seizure burden3 Predicted Language Score at 18 Months (Bayley-III) Median Seizure Burden 80 100 trend of
Slide 23: 2026 Strategic Objectives – Full Launch of Neonate and Pediatric
2026 Strategic Objectives of Core Seizure Market – Full Launch of Neonate and Pediatric Account Acquisition Drive Utilization in Existing Accounts • Execute on proven account acquisition strategy • Expand to new departments, ER, ICUs • Drive productivity of recently expanded commercial • Train more
Slide 24: Ceribell's Three Growth Horizons
Ceribell’s Three Growth Horizons LONGER TERM NEAR TERM Develop Solutions for Use Beyond the NOW Make EEG a New Vital Sign Acute Care Setting In Acute Care New Clinical Settings Seizure Management in the Acute Care Setting Indication Expansion in ICU and ED Biomarkers for Non-Acute Neurological & Psy
Slide 25: Ceribell's Goal: Make EEG A New Vital Sign
Ceribell’s Goal: Make EEG A New Vital Sign Stroke Seizure Delirium Other 25
Slide 26: 2025 Milestones Toward Making EEG a New Vital Sign
2025 Milestones Toward Making EEG a New Vital Sign Received FDA Clearance: Submitted NTAP application, based Delirium on previously received Breakthrough Delirium Algorithm Designation Unlocks >$1B market opportunity1 Received FDA Breakthrough Designation: Stroke LVO stroke detection algorithm in in
Slide 27: Delirium Represents a Significant Unmet Need
Delirium Represents a Significant Unmet Need Delirium, defined as an acute change in attention and awareness, often called “acute brain failure” High Prevalence Poor Clinical Outcomes Unmet Need • 3+ million patients in the • 1 ICU delirium day associated • Current diagnosis tool (CAM- US1-4 with 10
Slide 28: Delirium & Seizure: A Hidden Clinical Overlap
Delirium & Seizure: A Hidden Clinical Overlap Seizure 48% of ICU seizure patients experience delirium1 Similar presentation Delirium and Seizure Very different treatment approachs are Highly Interrelated 42% of ICU delirium patients have epileptiform abnormality 2 Delirium 1. Frei A.I., et al. (2023
Slide 29: 2026 Strategic Objectives of the Second Growth Horizon
2026 Strategic Objectives of the Second Growth Horizon Make EEGMake a New Vital Sign in Acute Care EEG a New Vital Sign In Acute Care Delirium LVO Stroke Hardware • Market development and • Advance product, clinical, and • Develop 2nd gen hardware commercial pilot regulatory development of with addi
Slide 30: Pipeline Programs Significantly Expand Ceribell's TAM
Pipeline Programs Significantly Expand Ceribell’s TAM Expanding to >$3.5B >$3.5B Market Opportunity TBD (U.S. Only) >$3.5B LVO Stroke + Potential Other New Indications >$1B $2.5B ICU Delirium Expansion ~$400M Pediatric & Neonate Expansion 3% >$2B Adult Seizure Market 2025 2026 2027 Beyond *Chart is
Slide 31: The First and Only
The First and Only FedRAMP® High Seizure Detection Algorithm Seizure Detection Algorithm Authorization for Preterm for Ages 1+ Delirium Detection Algorithm LVO Monitoring Algorithm FDA Cleared Breakthrough Designation 31
Slide 32: Clarity When It's Critical
ceribell Clarity When It’s Critical